Iranian Researcher Invents 1st Drug to Treat Obstructive Sleep Apnea

According to a report by the Public Relations Department of Birjand University of Medical Sciences in the Northeastern part of Iran, a contract was signed between Mohammed Mousavi Mirzaei, the inventor of a new medicine to treat obstructive sleep apnea and the German-Turkish company in the presence of the Iranian vice-president of the Center for Development and Development Cooperation.

The inventor of the world's first drug for obstructive sleep apnea who is the President of Birjand University of Medical Sciences said in that regard, “The exclusive owner of the company traveled to Iran several times in person to conduct negotiations and conclude the contract.”

“Due to the special nature and importance of this drug, many companies approached us for talks,” he added.

 He further said that verification is very important in concluding such contracts, and the parties to the contract were keen to sign it.

“The German and Turkish owner of the company visited several times and received sprays for verification given that claim made about the first drug for obstructive sleep apnea was very big and considering the special importance of this disease. After observing its remarkable therapeutic impact among the relatives and patients of users, he was very eager to conclude the contract, despite the fact that he did not know about its nature until moments before signing the contract,” said Mousavi Mirzaei who is a neurologist.

“98% of the terms of the contract were arranged by us, which shows the special importance of the product, and in the talks, considering the nature and acceptable effectiveness of the drug, the company finally agreed to accept most of our proposed terms,” the researcher said.

He added that the foreign company pledged to invest in Iran to start production for the first time under the name of of Iran and to expand production in the rest of the world, including Germany and Turkey.

“The fact that an experienced company makes a big commitment for itself, meaning that it is willing to lose a lot if the project fails in the global commercialization of this product, shows that the committed party believes in the certainty of the contract that it has concluded,” the researcher further said.

The discovery of medicne for obstructive sleep apnea was announced for the first time in the world by Dr. Mousavi Mirzaei last year after passing clinical trial phase successfully.

4155/i